Bayer Shrugs Off Xofigo Sales Pressure From Study Halt
Amid turmoil at Bayer's R&D unit, the company revealed that a Phase III trial of Xofigo had thrown up a safety issue for the product. Bayer insists peaks sales will be unaffected, but what had been a large potential new patient population now looks unlikely.
You may also be interested in...
The German major noted that the effects of the losses of patent protection on Xarelto and Eylea are still about five years down the line and it expects to be able to soften the blow with some future big-earners from the pipeline and more external deals.
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
Scrip caught up with Joerg Moeller, head of development at Bayer Pharmaceuticals, during the company's annual media day. Soon to take leadership of the German group's entire R&D organization, he talked about Bayer's R&D strategy and how the pharma industry will need to work with other healthcare stakeholders more collaboratively.